Posted in | Nanobusiness

Nanostart to Feature Successful Completion of MagForce Clinical Trials at Investor Presentation in NYC

Marco Beckmann, CEO of Nanostart AG, the global nanotechnology investment company based in Frankfurt, will be presenting the company and its portfolio holdings to an audience of approx. 80 selected investors and analysts on November 5 in New York City's Manhattan Club.

The occasion for this special investor event is first and foremost the superb results of clinical trials reported by MagForce Nanotechnologies AG (ISIN DE000A0HGQF5), which is 77% owned by Nanostart. On November 3, MagForce announced the successful completion of its clinical trials demonstrating the efficacy of its Nano-Cancer® therapy in treating recurrent glioblastoma, a particularly malignant form of brain tumor. The median survival time was more than doubled in the patient group, far in excess of the study objective. These clinical trials thus conclusively demonstrated the efficacy of Nano-Cancer® therapy. The study also confirmed that the therapy is extremely well tolerated by patients compared to conventional therapies, with no significant side effects.

The presentation will take place as part of an evening program. Marco Beckman will be in the spotlight as the event's sole speaker, and guests will have ample time following the formal presentation to speak individually with him and to ask detailed questions.

Vanessa Mieschke, responsible for investor relations at Nanostart, commented: “With these superb results from its clinical trials, our majority-owned MagForce is entering into a new era. Large U.S. investors have been awaiting these results with anxious anticipation.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback